We are studying whether adding belimumab to rituximab helps adults with persistent immune thrombocytopenia. This trial will compare the effects of the combination treatment to rituximab alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
Immune Thrombocytopenia (ITP) is a condition where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count. This can result in symptoms such as easy bruising, bleeding gums, and prolonged bleeding from cuts.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.